(DIR) Home
        
        
       Derm-Biome and TransBIOtech Awarded $450,000 ARD Grant Funding for
       Inflammatory Disease and Skin Aging Research
        
 (HTM) Source
        
       ----------------------------------------------------------------------
        
       Image credit: © New Africa - stock.adobe.com
        
       Derm-Biome Pharmaceuticals recently announced with its partner,
       TransBIOtech, that the companies have been awarded an Applied Research
       and Development (ARD) grant from the College and Community Innovation
       program of the Natural Sciences and Engineering Council of Canada in
       collaboration with the Social Sciences and Humanities Research Council
       and the Canadian Institutes of Health Research.1
        
       The $450,000 grant will span 3 years and will support Derm-Biome's
       research focus on inflammatory skin diseases and aging skin.
        
       Founded in 2018, Derm-Biome is a Vancouver-based preclinical
       biopharmaceutical company developing topical treatments for various
       inflammatory skin diseases, precancerous skin conditions, and non-
       melanoma skin cancers.
        
       "We are very pleased to have been awarded this Applied Research and
       Development grant and very much look forward to our continued working
       relationship with TransBIOtech in helping advance our exciting
       preclinical pipeline," said Gordon Eberwein, chief executive officer
       of Derm-Biome, in the news release.
        
       Frédéric Couture, principal investigator (PI) and the head of
       pharmaceutical sciences at TransBIOtech added, "This is very exciting
       news. We are happy to pursue this collaboration with Derm-Biome and
       help them propel their pipeline closer to new treatments. I believe
       that, along with co-PIs Dr. Sarah Paris-Robidas and Dr. Carole-Ann
       Huppé, our expertise in preclinical pharmacology in synergy with Derm-
       Biome's scientific team will accelerate future efficacy validation of
       their products and provide them with the key demonstrations needed for
       upcoming clinical trial applications."
        
       Derm-Biome is currently developing DB-007-04 for the treatment of
       acne, rosacea, atopic dermatitis, and aging skin.2
        
       According to Derm-Biome, in preclinical trials and animal models,
       DB-007-04 inhibits _C. acnes_ in acne, improves disease and itch
       scores in atopic dermatitis, and inhibits IL-17A and IL-17E to improve
       the health of aging skin.
        
       Derm-Biome is also developing DB-006 for the treatment of precancerous
       skin conditions such as actinic keratosis and skin cancers such as
       squamous cell carcinoma.
        
       In April 2024, Derm-Biome announced the results a UV-induced skin
       cancer trial where mice were exposed to UVB radiation over 25 weeks.
       Prolonged exposure to UVB mimics chronic sun exposure over time and
       replicates the gradual progression from precancerous skin conditions
       to cutaneous squamous cell carcinoma. Topical application of Derm-
       Biome's DB-006 compound prior to UVB exposure significantly reduced
       the number and size of precancer lesions, while treatment blocked the
       progression of squamous cell carcinoma tumors. Derm-Biomes expects to
       start topical formulation development of DB-006 in the summer of 2024,
       with Investigator New Drug Application-enabling studies planned to
       begin in the fourth quarter of 2024.3
        
        **References**
        
         1. Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Appl
         2. Skin conditions. Derm-Biome Pharmaceuticals. Accessed May 8, 2024
         3. Derm-Biome Pharmaceuticals' topical therapy shows positive result
        
        
        
        
       ______________________________________________________________________
                                                 Served by Flask-Gopher/2.2.1